Correlation of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with thrombolysis in myocardial infarction frame count in ST-segment elevation myocardial infarction

European Journal of Clinical Investigation

Volumn 47, Issue 4, 2017, Pages 322-327

  Vakili, Hossein ^a   Shirazi, Mahin ^a   Charkhkar, Mahsa ^a   Khaheshi, Isa ^a   Memaryan, Mehdi ^a   Naderian, Mohammadreza ^b,c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angioplasty; blood platelets; lymphocytes; neutrophil to lymphocyte ratio; neutrophils; percutaneous transluminal; platelet to lymphocyte ratio

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET LYMPHOCYTE RATIO; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR PATENCY; FIBRINOLYTIC THERAPY; LYMPHOCYTE; MIDDLE AGED; NEUTROPHIL; NO REFLOW PHENOMENON; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHYSIOLOGY; PROCEDURES; THROMBOCYTE;

BLOOD PLATELETS; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 85014539986     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12736     Document Type: Article

References (34)

1. GUSTO Angiographic Investigators. The effect tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615–22.
2. Balta S, Celik T, Mikhailidis DP, Ozturk C, Demirkol S, Aparci M et al. The relation between atherosclerosis and the neutrophil–lymphocyte ratio. Clin Appl Thromb Hemost 2016;22:405–11.
3. Durante A, Camici PG. Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol 2015;187:273–80.
4. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002;39:591–7.
5. Kurtul A, Yarlioglues M, Murat SN, Ergun G, Duran M, Kasapkara HA et al. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol 2014;114:342–7.
6. Mehta RH, Harjai KJ, Boura J, Cox D, Stone GW, O'Neill W et al. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 2003;92:1445–7.
7. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656–62.
8. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008;72:950–7.
9. Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol 2012;52:873–82.
10. Açar G, Kalkan ME, Avci A, Alizade E, Tabakci MM, Toprak C et al. The relation of platelet–lymphocyte ratio and coronary collateral circulation in patients with stable angina pectoris and chronic total occlusion. Clin Appl Thromb Hemost 2015;21:462–8.
11. Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis 2012;34:326–34.
12. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ et al. TIMI frame count a quantitative method of assessing coronary artery flow. Circulation 1996;93:879–88.
13. Gibson CM, Ryan KA, Kelley M, Rizzo MJ, Mesley R, Murphy S et al. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. Am Heart J 1999;137:1179–84.
14. Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F et al. Determinants of coronary blood flow after thrombolytic administration. J Am Coll Cardiol 1999;34:1403–12.
15. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35–53.
16. Kaya MG, Arslan F, Abaci A, van der Heijden G, Timurkaynak T, Cengel A. Myocardial blush grade: a predictor for major adverse cardiac events after primary PTCA with stent implantation for acute myocardial infarction. Acta Cardiol 2007;62:445.
17. Celik T, Iyisoy A, Yuksel UC, Jata B, Ozkan M. The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primary PCI in patients with acute myocardial infarction: the role of inflammation. Int J Cardiol 2009;136:86–8.
18. Sen N, Afsar B, Ozcan F, Buyukkaya E, Isleyen A, Akcay AB et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 2013;228:203–10.
19. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. TIMI Study Group. N Engl J Med 1985;312:932–6.
20. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel K-F, Neuhaus K-L. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993;21:1391–5.
21. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602–10.
22. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009;54:281–92.
23. Kaya MG, Akpek M, Lam YY, Yarlioglues M, Celik T, Gunebakmaz O et al. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. Int J Cardiol 2013;168:1154–9.
24. Oduncu V, Tanalp AC, Erkol A, Sırma D, Dündar C, Akgün T et al. Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol 2011;107:179–85.
25. Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M et al. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). Am J Cardiol 2007;99:1055–61.
26. Uğur M, Ayhan E, Bozbay M, Çiçek G, Ergelen M, Işık T et al. The independent association of plateletcrit with long-term outcomes in patients undergoing primary percutaneous coronary intervention. J Crit Care 2014;29:978–81.
27. Celık T, Balta S, Demır M, Yıldırım AO, Kaya MG, Ozturk C et al. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiol J 2016;23:84–92.
28. Linden MD, Furman MI, Frelinger AL 3rd, Fox ML, Barnard MR, Li Y et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007;5:761–5.
29. Zhang SZ, Jin YP, Qin GM, Wang JH. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-st elevation acute coronary syndromes. Clin Cardiol 2007;30:26–31.
30. Niederhuber JE. Cancer vaccines: the molecular basis for T cell killing of tumor cells. Oncologist 1997;2:280–3.
31. Balta S, Demırkol S, Kucuk U. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice. Hemodial Int 2013;17:668–9.
32. Sunbul M, Gerin F, Durmus E, Kivrak T, Sari I, Tigen K et al. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension. Clin Exp Hypertens 2014;36:217–21.
33. Kwon H-C, Kim SH, Oh SY, Lee S, Lee JH, Choi H-J et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216–22.
34. Akkaya E, Gul M, Ugur M. Platelet to lymphocyte ratio: a simple and valuable prognostic marker for acute coronary syndrome. Int J Cardiol 2014;177:597–8.